Non-small cell lung cancer

Open Access
Simultaneous Investigation of sST2, IL-33, and Caspase-3 Serum Levels in Non-small Cell Lung Cancer
FATMA TUBA AKDENIZ, ZERRIN BARUT, ORÇUN AVŞAR, SIBEL ARINÇ and TURGAY İSBIR

In Vivo November 2025, 39 (6) 3278-3286; DOI: https://doi.org/10.21873/invivo.14127
Open Access
Investigation of MicroRNA-30d-5p Expression and SOCS3 Levels in Non-small Cell Lung Cancer
SEHA AKDUMAN, SIBEL ARINÇ, MÜGE KOPUZ ÁLVAREZ NOVAL, SELVI DUMAN BAKIREZER, HUSEYIN KILILI and SEDA GÜLEÇ YILMAZ

In Vivo November 2025, 39 (6) 3308-3319; DOI: https://doi.org/10.21873/invivo.14106
Open Access
Tumor Location Is a Significant Predictor of Lymphovascular Invasion in Patients With Small-sized Non-small Cell Lung Cancer
TAKUMA TSUKIOKA, RYU NAKAJIMA, KYUKWANG CHUNG, SATOSHI OKADA, KAZUYA KISHIMOTO and HIROYUKI KOCHI

In Vivo November 2025, 39 (6) 3412-3417; DOI: https://doi.org/10.21873/invivo.14138
Open Access
Quantitative Analysis of CD27/CD70 Protein Expression and Investigation of Related Mechanisms in the Tumor Microenvironment of NSCLC
MERVE SAIDE UZUNOĞLU, AYLIN SEHER UZUNOĞLU, AKIF TURNA, VOLKAN KARA, ÖZLEM KÜÇÜKHÜSEYIN, CEM HOROZOĞLU and İLHAN YAYLIM

In Vivo September 2025, 39 (5) 2659-2668; DOI: https://doi.org/10.21873/invivo.14066
Open Access
Mitochondrial Damage-induced Ferroptosis: The Molecular Mechanism by Which Psoralen Inhibits the Proliferation and Invasion of Non-small-cell Lung Cancer Cells
HANGYU DENG, JINCHENG TANG, YUN XU, LING WU, JINGTING ZHANG, HONGYAO CHEN, ZHIBIN WANG, RENYI YANG, WENHUI GAO and ZUOMEI HE

In Vivo September 2025, 39 (5) 2681-2702; DOI: https://doi.org/10.21873/invivo.14068
Open Access
Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
MARTIN SVATON, MAGDALENA KNETKI-WROBLEWSKA, SYLWIA TABOR, PETR DOMECKY, ONDREJ VENCLICEK, JANA KREJCI, MARIE DROSSLEROVA, MICHAL HRNCIARIK, DANIEL HRICISAK, ALZBETA BEJCKOVA, ONDREJ FISCHER, MARTINA VITKOVA and MACIEJ KRZAKOWSKI

In Vivo September 2024, 38 (5) 2434-2440; DOI: https://doi.org/10.21873/invivo.13712
Open Access
Association of Nutritional Indices With Adverse Effects and Time-to-Treatment-Failure in Triple Therapy for Lung Cancer
YASUHISA HASHINO, TAKUMU MATUSHITA, TAE HATSUYAMA, AZUSA WAKAMOTO, KEISUKE GOTO, TAKANOBU HOSHI, KUNINORI IWAYAMA, KOICHI OHTAKI, TAKAKI TODA and HIDEKI SATO

In Vivo March 2024, 38 (2) 864-872; DOI: https://doi.org/10.21873/invivo.13512
Open Access
A Phase I Trial of Weekly Nab-paclitaxel Plus Carboplatin With Thoracic Radiotherapy for Non-small Cell Lung Cancer
TETSUYA KUBOTA, MIZU SAKAI, KAZUKI ANABUKI, KAZUFUMI TAKAMATSU, KENICHI MUKAIDA, KANA KOBAYASHI, TAKUJI YAMAGAMI and AKIHITO YOKOYAMA

In Vivo January 2024, 38 (1) 259-263; DOI: https://doi.org/10.21873/invivo.13433
Open Access
The Relationship Between Efficacy and Safety of Osimertinib Blood Concentration in Patients With EGFR Mutation-positive Lung Cancer: A Prospective Observational Study
YASUHISA HASHINO, TAE HATSUYAMA, KUNINORI IWAYAMA, TAKANOBU HOSHI, AZUSA WAKAMOTO, KOICHI OHTAKI, TAKAKI TODA and HIDEKI SATO

In Vivo November 2023, 37 (6) 2669-2677; DOI: https://doi.org/10.21873/invivo.13376
Open Access
Significance of Polar Charged Amino Acids in Compound Mutations in EGFR-mutated Patients Treated With First-line Afatinib
HIROAKI SATOH, YUIKA SASATANI, KUNIHIKO MIYAZAKI, YOSHIHARU SATO and NOBUYUKI HIZAWA

In Vivo July 2022, 36 (4) 1829-1833; DOI: https://doi.org/10.21873/invivo.12899

Main menu

User menu

Search

Non-small cell lung cancer

Pages